1. Introduction {#sec1}
===============

Neural tube defects (NTDs), a common group of central nervous system anomalies, comprise a major public health problem. It is estimated that approximately 300,000 babies are born each year with NTDs worldwide \[[@B1]\]. According to the World Health Organization (WHO) in 2010, an estimated 270,000 neonatal deaths globally were attributable to congenital anomalies, with NTDs being one of the most serious and most common of these anomalies \[[@B2], [@B3]\].

Both the birth and total prevalence of NTD have declined during the past three decades among high income countries \[[@B4]--[@B6]\]. Evidence suggests that the reduction in the birth prevalence of NTDs is largely due to termination of pregnancy after the introduction of routine serum alpha-fetoprotein measurements and advances in ultrasonography resolution for in utero early detection and termination of affected pregnancies \[[@B5], [@B6]\]. Additionally, improvements in folic acid supplementation have contributed to the reduction in total prevalence of NTDs \[[@B6]\]. For example, the incidence of myelomeningocele in Seattle, Washington, USA, was 5 per 10,000 births in 1981--1982, which then declined to 0.5 in 2001 \[[@B7]\]. The prevalence of NTDs in England and Wales was 38.0 per 10,000 live births in 1965, which steadily declined to 1.4 in 1997, a reduction of 96% \[[@B8]\]. Contrary to the developed world, prevalence of birth NTDs in developing countries is still high, with reported incidence as high as 130 per 10,000 births \[[@B9]\].

Data on the prevalence of NTDs are limited in lower-income countries despite the WHO resolution on birth defect surveillance \[[@B10]\]. A recent systematic review showed that many WHO member states (120/194) did not have any data on NTD prevalence \[[@B11]\]. Similarly, NTD prevalence in Ethiopia is not clearly known, and the country currently has no national preventive strategies. A retrospective chart review from Addis Ababa teaching hospitals revealed the overall prevalence of NTDs to be 6.1/1000 births \[[@B12]\]. The review concludes by recommending prospective studies to understand the real burden of NTDs.

Given the high prevalence of NTDs in the Ethiopian setting from retrospective data, it is imperative to investigate the burden and pattern of NTDs by prospectively following delivery outcomes. Moreover, to suggest plausible recommendations regarding preventive strategies against these disorders, risk factor assessment using a case-control design is important. In the current study, as there is no established preventive strategy for NTDs in Ethiopia \[[@B12], [@B13]\] and as the country is mostly a low income setting with low educational attainment and poor socioeconomic status, we hypothesize that the prevalence of NTDs in Ethiopia would be high and the risk factors associated with their occurrence are different from studies in high income settings. Hence, the current study sets out to investigate the prevalence of NTDs among pregnancy terminations and deliveries in major teaching hospitals in Addis Ababa. Additionally, the risk factors associated with NTDs are explored.

2. Methods and Materials {#sec2}
========================

2.1. Study Area, Period, and Design {#sec2.1}
-----------------------------------

The study was conducted in Addis Ababa, Ethiopia\'s largest urban center and capital city, with 3.3 million inhabitants with male to female ratio of 0.91 in 2013 \[[@B14]\]. According to Ethiopian Demographic and Health Survey (EDHS) 2011, the coverage of antenatal care (ANC) services, birth assistance by skilled provider, and postnatal care in the city were 93.6%, 83.9%, and 47.7%, respectively \[[@B13]\].

The current study used two study designs, namely, a prospective cross-sectional and a hospital-based case-control study. A prospective registration of all birth outcomes was conducted between February 1, 2016, and August 30, 2016, at three major hospitals in Addis Ababa to understand the prevalence of NTDs. An institution-based, unmatched case-control study was conducted to identify the risk factors associated with NTDs. The three hospitals, Tikur Anbessa Specialized Hospital (TAH), Zewditu Memorial Hospital (ZMH), and Gandhi Memorial Hospital (GMH), are the major teaching hospitals for Addis Ababa University. They provide 24-hour obstetrics and gynecology care for the city. The total number of annual deliveries in the three hospitals is more than 15,000 with a Cesarean section (CS) rate of 30--40%. Most of the deliveries and evaluations are made by obstetrics and gynecology residents under the supervision of senior obstetrician and gynecologists.

Sample size of the study was calculated separately for both the prevalence and risk factors to NTDs. For the prevalence, considering the prevalence of NTDs to be similar to a retrospective study in Addis Ababa of 6% \[[@B12]\], and using a single proportion formula at 95% CI and 0.5% margin of error, a total of 8,663 pregnant mothers had to be enrolled to have 80% power in estimating the burden of NTDs in the setting. Based on this sample size, and considering the delivery rate at the hospitals, at least a seven-month duration of data collection was decided. A total of 8,677 deliveries were evaluated during the predefined data collection period. For assessing risk factors for NTDs, using Epi Info, Stat Calc, and considering 95% confidence level (CI), 80% power, control to case ratio of 2, minimum odd ratio (OR) of 2, and 10% nonresponse gave a minimum sample of 111 cases of NTDS and 222 controls.

2.2. Data Collection Process and Analysis {#sec2.2}
-----------------------------------------

All intern doctors, residents, midwives, and clinical nurses were informed to report to the principal investigator whenever suspected cases of NTDs were delivered or medically terminated. Afterwards, data were collected by trained intern doctors and residents working at the selected hospitals in the postpartum or postabortal period and before discharge of the women. NTDs were defined as cases of anencephaly, spina bifida, and encephalocele (ICD-10) \[[@B15]\] among infants of any gestational age and medically terminated NTDs incompatible with life. Cases were ascertained by two senior obstetrics and gynecology residents by gross visual examination \[[@B16]\]. Radiologists used ultrasonography to perform prenatal diagnosis for termination of pregnancy, and senior obstetrics and gynecology residents confirmed diagnoses after expulsion by gross appearance of the abortus.

For the case-control design, to assess risk factors for NTDs, for each confirmed case of NTD, two mother-baby dyads with a normal delivery were selected systematically from that same day\'s delivery list of the same hospital. Cases with any ambiguity or multiple congenital anomalies were excluded from the study to avoid misclassification. Live birth or stillbirth was considered after 28 weeks of gestation or birth weight of 1,000 gm and greater. Elective termination of pregnancy for NTDs was made after 12 weeks of gestations and diagnosis via ultrasonography. NTDs cases were identified and ascertained within one week of birth or termination.

Data were collected by face-to-face interviews using a structured questionnaire adapted from the WHO birth defect surveillance tool \[[@B16]\]. Data were entered and analyzed using SPSS version 20 statistical package. The prevalence of NTDs calculated for both birth prevalence and total prevalence per 10,000 based on birth outcomes \[live births (LBs), stillbirths (SBs), and terminated pregnancy\]. Birth prevalence of NTDs is defined as number of cases of LBs or SBs with NTDs after 28 weeks of gestation (numerator) among a total number of LBs plus SBs during the study period. Total prevalence of NTDs is defined as number of NTD cases of LBs, SBs, and terminated pregnancy for fetal NTDs (numerator) among a total of LBs, SBs, and terminated cases beyond 12 weeks of gestation during the study period. The 95% CI for prevalence of NTDs was calculated using the binomial distribution as the number of cases in each category was greater than 30. Both bivariate and multivariate analyses were done to identify risk factors of NTDs. Out of the total independent variables, *p* values of less than 0.25 were taken for multivariate analysis. Stepwise backward multivariate logistic regression analysis was used to identify the best model with maximum predictive ability, which was used for final analysis. *p* value less than 0.05 was used as cut-off point for multivariate analysis.

In the current study, preconception was used to refer to the preceding three months before conception, while periconception was used to refer to the period including three months before conception (preconception) and the first three months after conception (first trimester). Preconception care is any type of care (health promotion, treatment, and supplementation) provided to a woman before conception. Drugs in this study means both prescribed pharmaceuticals and over the counter medications, not drugs used for recreations.

2.3. Ethical Consideration {#sec2.3}
--------------------------

Ethical clearance was obtained from the institutional review board (IRB) of College of Medicine and Health Sciences of Addis Ababa University (CMHS, AAU). A formal letter obtained from CHMS, AAU requesting permission to cascade the study was sent to each hospital\'s medical director. After the purpose of the study was described to the participating women, written consent was obtained from each one of them. In order to maintain confidentiality of any information provided by study subjects, the data collection procedure was anonymous. Participants with NTDs were counselled about the condition of their baby on the day following their delivery and the benefits of preconception folic acid supplementation to decrease future recurrence of NTDs.

3. Results {#sec3}
==========

3.1. Sociodemographic Characteristics of the Participants {#sec3.1}
---------------------------------------------------------

A majority of the cases (94.6%) and controls (94.1%) were from Addis Ababa. There was no difference between the mean age of cases (26.9; ±4.6) and controls (26.7; ±5.2) (*p* value; 0.193). Moreover, there was no difference between the cases and controls in terms of the participants\' religion, marital status, educational status, family size, and occupation. However, there was a statistically significant difference in prepregnancy body mass index (BMI) (*p* value; 0.041) and family annual cash income (*p* value; 0.032) \[[Table 1](#tab1){ref-type="table"}\].

3.2. Obstetric History of Participants {#sec3.2}
--------------------------------------

There was no difference between the cases and controls in terms of history of abortion (*p* value; 0.198), stillbirth (*p* value; 0.364), and congenital anomaly birth (*p* value; 0.820). There were three (2.7%) cases of congenital anomaly (all NTDs) in the cases, and seven (3.2%) cases of congenital anomaly (five NTDs and two congenital heart diseases) in the controls. Out of those with anomaly birth history, none of the cases and 85.7% of the controls had preconception folic acid supplementation, which is a statistically significant difference (*p* value; 0.033) \[[Table 2](#tab2){ref-type="table"}\].

3.3. Periconceptional Characteristics of the Study Participants {#sec3.3}
---------------------------------------------------------------

Out of the total participants, 40.5% (24.3% cases and 16.2% controls) of the pregnancies were unplanned (*p* value; 0.075). One-third (30.6%) of the participants (9.9% cases and 20.7% controls) had preconception care, which is significantly different between cases and controls (*p* value; 0.014). However, only 14.4% of the participants (5.4% cases and 9% controls) had preconception folic acid or multivitamin supplementation (*p* value; 0.364). There was a significant difference (*p* value; 0.001) between cases (3.5%) and controls (30.6%) for use of folic acid or multivitamin in the first three months after conception \[[Table 3](#tab3){ref-type="table"}\].

3.4. Prevalence of Neural Tube Defects {#sec3.4}
--------------------------------------

During the study period, there were a total of 8,677 births after the 28th week of gestation. A total of 115 pregnancies were terminated between the 12th and 28th weeks of gestation; of these, 56 pregnancies were terminated because of presence of NTDs. A total of 55 cases of NTDs were documented after the 28th week of gestation. The overall prevalence of NTDs after 12 weeks of gestation was found to be 126 per 10,000 births (95% CI, 100--150). Among live births and stillbirths, excluding medically terminated cases, the birth prevalence of NTDs was 63.4 per 10,000 births (LBs and SBs) (95% CI, 51--77).

Anencephaly (68 cases per 10,000 births), spina bifida (51 cases per 10,000 births), and encephalocele (seven cases per 10,000 births) were the most common types of the NTDs. Excluding terminated cases as a prevention, the birth prevalence of anencephaly was 17.3 cases per 10,000 live and stillbirths; prevalence of encephalocele was 3.5 cases per 10,000 live and stillbirths; and spina bifida prevalence was 40 cases per 10,000 live and stillbirths \[[Figure 1](#fig1){ref-type="fig"}\].

3.5. Characteristics of Neural Tube Defects {#sec3.5}
-------------------------------------------

Out of the total cases of NTDs, 54.1% were cases of anencephaly; 40.5%, spina bifida; and 5.4%, encephalocele. Diagnosis of NTDs was made by ultrasound before birth for 96/111 (86.5%) cases, while the remaining cases were diagnosed at birth even though there was at least one ultrasound scan during ANC. The mean gestational age at diagnosis was 25 weeks (±8) and the mean gestational age at delivery or termination was 29 weeks (±9) \[[Table 4](#tab4){ref-type="table"}\].

3.6. Risk Factors Related to Neural Tube Defects {#sec3.6}
------------------------------------------------

Family annual cash income, drug use in the first three months of conception, sex of the baby, prepregnancy BMI, and whether the pregnancy was planned or not were independent predictors of neural tube defects. Women who used either folic acid or multivitamins containing folic acid during the first three months of conception were 53% less likely (aOR, 0.47; 95%, 0.23, 0.95) to have NTDs than those who did not take any supplements. Though not statistically significant, women who used any other drugs than folic acid or multivitamins were two times (aOR, 2.12; 95%, 0.98, 4.56) more likely to have NTDs.

Women who had planned pregnancies were 53% less likely (aOR, 0.47; 95%, 0.24, 0.92) to have NTDs as compared to unplanned pregnancies. Male sex was associated with a 44% reduction in the risk of NTDs as compared to female sex (aOR, 0.56; 95%, 0.33, 0.94); however, we have not seen differences between male versus females for anencephaly and spina bifida (anencephaly, 53.8% versus 54.2%; encephalocele, 2.0% versus 8.5%; and spina bifida, 32.7% versus 34.0%, resp.). Women who had a normal or an underweight prepregnancy BMI were 51% less likely to have NTDs than those who were overweight or obese (aOR, 0.49; 95%, 0.29, 0.93). Women with annual family cash income of less than \$1,300 USD (aOR, 2.50; 95%, 1.21, 5.52), \$1,300--1,800 USD (aOR, 2.82; 95%, 1.33, 5.81), and \$1,801--2,700 USD (aOR, 2.64; 95%, 1.21, 5.82) were almost 2.5 times more likely to have NTDs, compared to those with annual cash incomes of greater than \$2,700 USD \[[Table 5](#tab5){ref-type="table"}\].

4. Discussion {#sec4}
=============

Because birth defects are a major cause of mortalities before five years of age, adequate surveillance data are needed to develop plausible prevention strategies. This is particularly important for birth defects that can be prevented via well-established interventions, like NTDs \[[@B1]--[@B3]\]. Although many births in Ethiopia occur outside of health institution \[[@B13]\], institution-based prevalence studies give some insight into the prevalence and risk factors of NTDs. Such evidence might be a starting point for countries with limited resources like Ethiopia to start a hospital-based NTDs surveillance program that may then develop to a population-based surveillance \[[@B16]\].

In this study of more than 8,000 births, the total prevalence for all types of NTDs was found to be 126 per 10,000 births, and the birth prevalence for all types of NTDs was found to be 63.4 per 10,000 births. This finding is one of the highest NTDs prevalence reported in Africa. It is higher than reports from Yaoundé, Cameroon (18.6 per 10,000) \[[@B17]\]; Democratic Republic of Congo (10.2 per 10,000) \[[@B18]\]; Blantyre, Malawi (6.3 per 10,000) \[[@B19]\]; Cross River and Akwa Ibom states of Nigeria (5.2 per 10,000) \[[@B20]\]; South Africa (9.8 per 10,000) \[[@B21]\]; and Dares Salaam, Tanzania (30.2 per 10,000) \[[@B22]\]. It is higher than most of the Eastern Mediterranean regions including Egypt (16 per 10,000) \[[@B23]\]; Southwest Iran (38.1 per 10,000) \[[@B24]\]; Western Iraq (27.9 per 10,000) \[[@B25]\]; Sudan (33.7 per 10,000) \[[@B26]\]; and the Al-Jahra region of Kuwait (6.5 per 10,000) \[[@B27]\]. It is also higher than all European countries (EUROCAT) \[[@B28], [@B29]\] and many Southeast Asian regions including Bangladesh (13.8 per 10,000) \[[@B30]\]; Eastern India (17.8 per 10,000) \[[@B31]\]; Nepal (11.9 per 10,000) \[[@B32]\]; and Bangkok, Thailand (6.3 per 10,000) \[[@B33]\]. Reports of similar prevalence to our study have emerged from Northern China (199.4 per 10,000 births) \[[@B34]\]; Eastern Saudi Arabia (53.5 per 10,000) \[[@B35]\]; Jordan (62.9 per 10,000) \[[@B36]\]; Iran (82.9 per 10,000) \[[@B37]\]; and Algeria (75.4 per 10,000) \[[@B38]\]. Consistently high prevalence of NTDs similar to our study has also been reported in Swat (124 per 10,000) \[[@B39]\] and Abbottabad (68.8 per 10,000) \[[@B40]\] regions of Pakistan.

These variations might be explained by the influence of racial, geographical, nutritional, socioeconomic, and biological differences. Rates may also be affected by the differences in national NTDs prevention intervention programs in various countries \[[@B41]\]. Settings and designs could also affect findings from different studies. Referral hospitals would be expected to have higher rates than population-based studies, as many cases are referred to these hospitals for termination and diagnosis of NTDs. Methods of case ascertainment, gestational age at prenatal diagnosis, and infant ages at diagnosis as well as inclusion/exclusion of electively medically terminated cases of NTDs could also vary.

Findings of the current study should be interpreted with caution for the following reasons. First, hospital-based studies may overestimate prevalence of NTDs. Second, our study included medically terminated cases of NTDs, while most other studies report on live births and stillbirths only. Conversely, the high NTDs rate we found in our study could also be the actual prevalence for the study area given similar findings from another retrospective study in the same area \[[@B12]\]. This high prevalence could result from nutritional factors, genetics, lack of routine folic acid supplementation, and absence of folic acid fortification programs. In our study, half of the women started ANC after three months of gestation and only 25% of women had folic acid supplementation in the first 12 weeks of gestation, which is the critical period of supplementation \[[@B42]\].

Our study highlighted the importance of folic acid and/or multivitamin supplementation during the first three months of conception for prevention of NTDs. This finding is in line with other studies worldwide \[[@B43], [@B44]\] and international recommendations of folic acid supplement for women from the moment they attempt to conceive until 12 weeks of pregnancy \[[@B45]\]. Despite the WHO periconceptional folic acid supplementation recommendations, studies showed that many women still do not follow the recommendations, particularly women of low socioeconomic status \[[@B46]\]. This is also true in our study; though 17% of the participants had preconception care, only 7.8% were supplemented \[[Table 3](#tab3){ref-type="table"}\].

The association between prepregnancy BMI and occurrence of NTDs was similarly reported elsewhere \[[@B47], [@B48]\]. This may be because NTD-protective effect of folic acid supplementation is weaker in overweight/obese mothers \[[@B49]\] and obese women may require higher doses of folic acid supplementation to achieve similar serum levels \[[@B50]\]. Regarding the nonmodifiable factors, though the contribution of sex to NTDs is controversial and no plausible biologic explanation is known, other studies report similar findings \[[@B51], [@B52]\]. Higher rates of NTDs have been reported in populations with lower socioeconomic status from Europe and the USA \[[@B53]\]. Our study found similar associations even though we did not measure economic status based on wealth quantile \[[@B13]\], possibly due to factors like housing condition, frequency of infections, and deficiency of dietary factors such as the intake of vitamins and folic acid.

5. Conclusion {#sec5}
=============

The prevalence of neural tube defects at three hospitals in Addis Ababa was found to be higher than other reports from Africa, Europe, America, and many Asian countries. Our finding is consistent with previous findings. Comprehensive preventive strategies focused on the identified risk factors should be urgently established. Moreover, studies on preventive strategies including folic acid supplementation should be conducted in these settings.
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Additional Points
=================

*Strength/Limitations of This Study*. This study has several strengths. First, it included data from evaluation of more than 8,000 births and cases of terminated pregnancy. Second, it employed the principles of active surveillance of case detection so that the risk of missed cases of NTDs was minimized. Finally, analyses were based on all birth outcomes (stillbirths, live births, and terminated pregnancy). Data were also collected in the immediate postpartum period to minimize the recall bias of the periconceptional event.

Although not unique to this study, a potential limitation is participant recall and self-report of risk factors, which could introduce bias. The self-reported nature of the information income and other related factors are also a limitation of this study. It is a hospital-based study and could have missed many deliveries which occurred outside hospitals.
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###### 

Sociodemographic characteristics of the study participants, Addis Ababa University Teaching Hospitals, Ethiopia, February 1 to August 30, 2016 (*n* = 333).

  Variables                          Case (%)     Controls (%)   *p* value
  ---------------------------------- ------------ -------------- -----------
  Residence                                                      0.867
   Addis Ababa                       105 (94.6)   209 (94.1)      
   Outside Addis Ababa               6 (5.4)      13 (5.9)        
  Age of participants (mean; SD)     26.9; ±4.6   26.7; ±5.2     0.193
   ≤20                               12 (10.8)    18 (8.1)        
   21--25                            44 (39.6)    74 (33.3)       
   26--30                            35 (31.5)    84 (37.8)       
   31--35                            12 (10.8)    38 (17.1)       
   \>35                              8 (7.2)      8 (3.7)         
  Age of partners (mean; SD)         32.0; ±7     32.5; ±7       0.252
   20--29                            42 (37.8)    82 (36.9)       
   30--39                            57 (51.4)    101 (45.5)      
   ≥40                               12 (10.8)    39 (17.6)       
  Religion                                                       0.929
   Christian                         83 (74.8)    165 (74.3)      
   Muslim                            28 (25.2)    7 (25.7)        
  Marital status                                                 0.339
   Married                           106 (95.5)   206 (92.8)      
   Others                            5 (4.5)      16 (7.2)        
  Educational status                                             0.532
   No formal education               14 (12.6)    23 (10.4)       
   Primary school                    46 (41.4)    78 (35.1)       
   Secondary school                  28 (25.2)    68 (30.6)       
   Above secondary                   3 (20.7)     53 (23.9)       
  Partner education status                                       0.269
   No formal education               10 (9)       20 (9)          
   Primary school                    37 (33.3)    52 (23.4)       
   Secondary school                  30 (27)      67 (30.2)       
   Above secondary                   34 (30.6)    83 (37.4)       
  Occupation                                                     0.104
   Employed                          31 (27.9)    62 (27.9)       
   Merchant                          10 (9)       43 (19.4)       
   Daily laborer                     12 (10.8)    29 (13.1)       
   Housewife                         58 (52.3)    88 (39.6)       
  Family size (mean; SD)             3.0; ±1.2    3.2; ±1.3      0.061
   ≤3                                81 (73)      139 (62.6)      
   \>3                               30 (27)      83 (37.4)       
  Family annual cash income (USD)    889; ±964    2310; ±1605    0.032
  (mean; SD)                                                      
   \$\<1300                          29 (26.1)    49 (22.1)       
   \$1300--1800                      35 (31.5)    55 (24.8)       
   \$1801--2700                      27 (24.3)    43 (19.4)       
   \$\>2700                          20 (18)      75 (33.8)       
  Prepregnancy BMI (mean; SD)        23; ±3.1     22; ±2.8       0.041
   \<24.9                            85 (76.6)    190 (85.6)      
   ≥25                               26 (23.4)    32 (14.4)       

BMI: body mass index; SD: standard deviation; USD: United States Dollar.

###### 

Obstetric histories of the study participants, Addis Ababa University Teaching Hospitals, Ethiopia, February 1 to August 30, 2016 (*n* = 333).

  Variables                                             Case (%)     Control (%)   *p* value
  ----------------------------------------------------- ------------ ------------- -----------
  Previous history of abortion                                                     0.198
   Yes                                                  21 (18.9)    56 (25.2)      
   No                                                   90 (81.1)    166 (74.8)     
  Parity (mean ± SD)                                    1.2 (±1.1)   1.9 (±1.1)    0.289
   Nulliparous                                          33 (29.7)    0 (0)          
   Prim parous                                          45 (40.5)    105 (47.3)     
   Multiparous                                          33 (29.7)    117 (52.7)     
  END^*∗*^ history                                                                 **0.042**
   Yes                                                  7 (6.3)      4 (1.8)        
   No                                                   104 (93.7)   218 (98.2)     
  Stillbirth history                                                               0.364
   Yes                                                  2 (1.8)      8 (3.6)        
   No                                                   109 (98.2)   214 (96.4)     
  Congenital anomaly birth History                                                 0.820
   Yes                                                  3 (2.7%)     7 (3.2)        
   No                                                   108 (97.3)   215 (96.8)     
  Types of congenital anomaly (*n* = 10)                                            
   Cardiac                                              0 (0)        2 (28.6)      
   NTDs^*∗∗∗*^                                          3 (100)      5 (71.4)      
  Preconception folic acid supplementation (*n* = 10)                              **0.033**
   Yes                                                  0 (0)        6 (85.7)       
   No                                                   3 (100)      1 (14.3)       
  Number of index Pregnancy                                                        0.334
   Singleton                                            108 (97.3)   211 (95)       
   Twin                                                 3 (2.7)      11 (5)         
  Sex                                                                              0.074
   Male                                                 52 (46.8)    127 (57.2)     
   Female                                               59 (53.2)    95 (42.8)      
  ANC^*∗∗*^ initiation time                                                        **0.003**
   1st trimester                                        46 (41.4)    127 (57.2)     
   2nd trimester                                        63 (56.8)    83 (37.4)      
   3rd trimester                                        2 (1.8)      12 (5.4)       
  Place of ANC                                                                     0.014
   Private                                              10 (9)       17 (7.7)       
   clinic/hospital                                                                  
   Health center                                        93 (83.8)    158 (71.2)     
   Public hospitals                                     7 (6.3)      44 (19.8)      
   No ANC                                               1(.9)        3 (1.4)        

^*∗*^Early neonatal death. ^*∗∗*^Antenatal care. ^*∗∗∗*^Neural tube defects.

###### 

Periconceptional characteristics of the study participants, Addis Ababa University Teaching Hospitals, Ethiopia, February 1 to August 30, 2016 (*n* = 333).

  Variables                                Cases (%)    Controls (%)   *p* value
  ---------------------------------------- ------------ -------------- -----------
  Any chronic illness before conception                                0.104
   Yes                                     6 (5.4)      24 (10.8)       
   No                                      105 (94.6)   198 (89.2)      
  Current pregnancy type                                               0.075
   Planned                                 84 (75.7)    186 (83.8)      
   Unplanned                               27 (24.3)    36 (16.2)       
  Remember current LNMP^*∗*^                                           0.108
   Yes                                     77 (69.4)    134 (60.4)      
   No                                      34 (30.6)    88 (39.6)       
  Contraceptive use before conception                                  0.072
   Yes                                     55 (49.5)    133 (59.9)      
   No                                      56 (50.5)    89 (40.1)       
  Preconception care                                                   **0.014**
   Yes                                     11 (9.9)     46 (20.7)       
   No                                      100 (90.1)   176 (79.3)      
  Preconception drugs use                                              0.364
   Folic acid/multivitamins                6 (5.4)      20 (9)          
   Any other drugs                         3 (2.7)      3 (1.4)         
   None                                    102 (91.9)   199 (89.6)      
  Any attempt to terminate the pregnancy                               0.076
   Yes                                     5 (4.5)      3 (1.4)         
   No                                      106 (95.5)   219 (98.6)      
  Drugs use in the 1st trimester                                       **0.001**
   Folic acid/multivitamins                15 (13.5)    68 (30.6)       
   Any other drugs                         22 (19.8)    23 (10.4)       
   None                                    74 (66.7)    131 (59.0)      

^*∗*^Last normal menstrual period.

###### 

Characteristics of neural tube defects, Addis Ababa University teaching hospitals, Ethiopia, February 1 to August 30, 2016 (*n* = 111).

  ------------------------------------------------------------------------------------------------
  Variables                                         Frequency   Percentage   Remark
  ------------------------------------------------- ----------- ------------ ---------------------
  Types of NTDs                                                               

   Anencephaly                                      60          54.1         

   Spina bifida                                     45          40.5         

   Encephalocele                                    6           5.4          

  Time at diagnosis                                                          

   Antenatal                                        96          86.5         

   At birth                                         15          13.5         

  US^*∗*^ scan done for at birth diagnosis                                   *n* = 15

   Yes                                              13          86.7          

   No                                               2           13.3          

  Gestational age at Diagnosis (weeks) (*n* = 96)                            Mean = 25 (±8)

   \<24                                             47          42.3          

   24--27^6/7^                                      18          16.2          

   28--33^6/7^                                      12          10.8          

   34--36^6/7^                                      8           7.2           

   ≥37                                              11          9.9           

  Gestational age at Delivery/expulsion (weeks)                              Mean = 29 (±9) \
                                                                              Median = 27.7

   \<24                                             35          31.5          

   24--27^6/7^                                      21          18.9          

   28--33^6/7^                                      15          13.5          

   34--36^6/7^                                      6           5.4           

   ≥37                                              34          30.6          

  Mode of delivery/termination                                                

   Spontaneous vaginal delivery                     38          34.2         

   Induced vaginal delivery                         58          52.3         

   Cesarean section                                 8           7.2          

   Destructive vaginal delivery                     7           6.3          

  Admission to delivery/expulsion in days                                    Mean = 3.2 (±2.2) \
                                                                               Median = 3

   1 day                                            40          36.0          

   2--4 days                                        44          39.6          

   ≥5 days                                          27          24.3          
  ------------------------------------------------------------------------------------------------

^*∗*^Ultrasound.

###### 

Logistic regression analysis on determinants of neural tube defects, Addis Ababa University Teaching Hospitals, Ethiopia, 2016 (*n* = 333).

  Variables                               Neural tube defects   *p* value   OR (95% CI)                              
  --------------------------------------- --------------------- ----------- ------------------- -------------------- -----------------------
  *Annual family cash income (USD)*                                         0.032                                     
   \<\$1300                               29                    49                              2.2 (1.13--4.35)     **2.50 (1.21--5.52)**
   \$1300--1800                           35                    55                              2.39 (1.25--4.57)    **2.82 (1.33--5.81)**
   \$1801--2700                           27                    43                              2.36 (1.18--4.69)    **2.64 (1.21--5.82)**
   \>\$2700                               20                    75                              1                    1
  *Drugs in the 1st trimester*                                              **0.001**                                 
   Folic acid/multivitamins               15                    68                              0.39 (0.28--0.73)    **0.47 (0.23--0.95)**
   Any other drugs                        22                    23                              1.69 (0.88--3.25)    2.12 (0.98--4.56)
   None                                   74                    131                             1                    1
  *Prepregnancy BMI*                                                        0.043                                     
   \<24.9                                 85                    190                             0.55 (0.31--0.98)    **0.49 (0.29--0.95)**
   ≥25                                    26                    32                              1                    1
  *Place of ANC*                                                            0.022                                     
   Private clinic/hospital                10                    17                              1.77 (0.16--19.3)    8.34 (0.57--121.3)
   Health center                          93                    158                             1.77 (0.18--17.2)    4.76 (0.41--55.67)
   Public hospitals                       7                     44                              0.48 (0.04--5.26)    1.68 (0.12--22.75)
   No ANC                                 1                     3                               1                    1
  *END history*                                                             0.042                                     
   Yes                                    7                     4                               3.67 (1.05--12.80)   4.15 (0.95--18.16)
   No                                     104                   218                             1                    1
  *Contraceptive use before conception*                                                                               
   Yes                                    55                    133         0.66 (0.42--1.04)   0.67 (0.40--1.12)    
   No                                     56                    89          1                   1                    
  *Outcome (sex)*                                                           0.075                                     
   Male                                   52                    127                             0.66 (0.42--1.04)    **0.56 (0.33--0.94)**
   Female                                 59                    95                              1                    1
  *Pregnancy type*                                                          0.077                                     
   Planned                                84                    186                             0.60 (0.34--1.06)    **0.47 (0.24--0.92)**
   Unplanned                              27                    36                              1                    1
  *Remember LNMP*                                                           0.109                                     
   *Yes*                                  77                    134                             1.49 (0.92--2.41)    1.96 (0.98--3.40)
   *No*                                   34                    88                              1                    1
  *Preconception care*                                                      0.016                                     
   Yes                                    11                    46                              0.42 (0.21--0.85)    0.50 (0.21--1.21)
   No                                     100                   176                             1                    1

END: early neonatal death; BMI: body mass index; ANC: antenatal care; LNMP: last normal menstrual period.
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